Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NVCR
NVCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCR News
NovoCure Under Investigation for Possible Securities Fraud
15h ago
Globenewswire
NovoCure Under Investigation for Possible Securities Fraud
Jun 30 2026
Globenewswire
NovoCure Under Investigation for Securities Fraud Claims
Jun 25 2026
PRnewswire
Investment Choices Between HeartFlow and NovoCure: Diagnostics vs. Therapeutics
Jun 24 2026
Fool
Investment Comparison Between NovoCure and Omeros
Jun 22 2026
Fool
Comparing Investment Prospects of Amgen and NovoCure
Jun 19 2026
NASDAQ.COM
Investment Analysis: Amgen vs. NovoCure
Jun 19 2026
Fool
Novocure's Phase 3 Trial Fails, Shares Plunge Over 18%
Jun 19 2026
Newsfilter
Novocure's TRIDENT Trial Fails to Meet Primary Endpoint
Jun 19 2026
PRnewswire
US Stocks Rise on US-Iran Peace Deal Optimism
Jun 18 2026
NASDAQ.COM
US Stocks Surge as Geopolitical Risks Ease
Jun 18 2026
NASDAQ.COM
US Stocks Surge as Chipmakers Lead Gains Amid Positive Economic News
Jun 18 2026
NASDAQ.COM
Novocure Faces Setback in Cancer Treatment Device Trial
Jun 18 2026
seekingalpha
Novocure Announces TRIDENT Trial Results for Glioblastoma
Jun 18 2026
Newsfilter
NovoCure CEO Frank Leonard Sells 34,273 Shares for $615,000
Jun 09 2026
Fool
NovoCure CEO Sells 34,273 Shares for $615,000
Jun 09 2026
NASDAQ.COM
Show More News
